Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 60498
Gene Symbol: IGAN1
IGAN1
0.100 GeneticVariation disease BEFREE Renal biopsy specimens were obtained from five patients with IgA nephropathy (IgAN), five patients with membranous nephropathy (MN) and five kidney transplant donors (as controls). 31707756 2020
Entrez Id: 60498
Gene Symbol: IGAN1
IGAN1
0.100 GeneticVariation disease BEFREE Focal segmental glomerulosclerosis (FSGS) was the commonest primary GN accounting for 18.2% of all GNs, followed by minimal change disease (16.8%), membranous nephropathy (MN) (16.0%) and IgA nephropathy (10.4%). 30834630 2020
Entrez Id: 60498
Gene Symbol: IGAN1
IGAN1
0.100 Biomarker disease BEFREE To investigate this hypothesis, we first measured urine exosomal and kidney expression of CP in non-diabetic chronic kidney disease (CKD) patients (membranous nephropathy, focal segmental glomerulosclerosis, lupus nephritis and IgA nephropathy) followed by a longitudinal study in rat passive Heymann nephritis (PHN), a model of human membranous nephropathy. 30955187 2019
Entrez Id: 60498
Gene Symbol: IGAN1
IGAN1
0.100 Biomarker disease BEFREE In 7 (10%) of 69 PLA<sub>2</sub>R1-antibody-negative patients, renal biopsies showed an additional diagnosis to membranous nephropathy: one (1%) case of IgA nephropathy, cholesterol emboli, IgG4-related disease, necrotising glomerulonephritis, thrombotic microangiopathy, interstitial nephritis and diabetic nephropathy each. 30962506 2019
Entrez Id: 60498
Gene Symbol: IGAN1
IGAN1
0.100 Biomarker disease BEFREE In this respect, the reported renal pathologies were IgA nephropathy, crescentic glomerulonephritis, acute renal artery occlusion, acute tubulointerstitial nephritis (ATIN), FSGS, and membranous glomerulopathy. 30673815 2019
Entrez Id: 60498
Gene Symbol: IGAN1
IGAN1
0.100 GeneticVariation disease BEFREE This included 401 patients with membranous nephropathy (MN), 824 patients with IgA nephropathy (IgAN), 385 patients with focal segmental glomerulosclerosis (FSGS), 397 patients with lupus nephritis (LN) and 399 patients with ANCA-related glomerulonephritis (ANCA-GN). 31113679 2019
Entrez Id: 60498
Gene Symbol: IGAN1
IGAN1
0.100 Biomarker disease BEFREE Comparing to IgA nephropathy, the adjusted HR was highest for DN [aHR = 2.97, 95% confidence interval (CI) 2.77-3.20], next highest for lupus nephritis (aHR = 1.86, 95% CI 1.71-2.03), and thereafter ranged from 1.29 (95% CI 1.19-1.39) in autosomal dominant polycystic kidney disease to 1.67 (95% CI 1.52-1.83) in membranous nephropathy. 30085056 2019
Entrez Id: 60498
Gene Symbol: IGAN1
IGAN1
0.100 Biomarker disease BEFREE This report covers general management of glomerular disease, IgA nephropathy, and membranous nephropathy. 30665568 2019
Entrez Id: 60498
Gene Symbol: IGAN1
IGAN1
0.100 Biomarker disease BEFREE Among the patients who developed focal segmental glomerulosclerosis (FSGS; n = 13), IgA nephropathy (IgAN; n = 10), IgAN with morphological presentation of focal segmental glomerulosclerosis (IgAN/FSGS; n = 8), membranous nephropathy (MN; n = 12), and lupus nephritis (LN; n = 6) were included in the analysis. 31067548 2019
Entrez Id: 60498
Gene Symbol: IGAN1
IGAN1
0.100 Biomarker disease BEFREE Comparison with membranous nephropathy and IgA nephropathy showed no significant difference. 31089477 2019
Entrez Id: 60498
Gene Symbol: IGAN1
IGAN1
0.100 Biomarker disease BEFREE Pathological results showed 3 types of glomerulonephritis, including 9 cases of MCD, 2 cases of IgA nephropathy, and 1 case of MN. 31387106 2019
Entrez Id: 60498
Gene Symbol: IGAN1
IGAN1
0.100 Biomarker disease BEFREE Furthermore, the downregulation of plasma-miRNA signature was not detected in disease controls (n = 119) such as IgA nephropathy (IgAN), mesangial proliferative glomerulonephritis (MSPGN), and membranous nephropathy (MN), and the miRNA panel discriminated between FSGS and disease controls. 29748623 2018
Entrez Id: 60498
Gene Symbol: IGAN1
IGAN1
0.100 GeneticVariation disease BEFREE Among primary glomerulonephritis, IgA nephropathy (26.0%), focal segmental glomerulosclerosis (21.6%), and membranous nephropathy (20.6%) were most frequently diagnosed. 29320993 2018
Entrez Id: 60498
Gene Symbol: IGAN1
IGAN1
0.100 Biomarker disease BEFREE We studied 315 participants in the Nephrotic Syndrome Study Network (NEPTUNE) study, including biopsy-proven minimal change disease (MCD = 98), focal segmental glomerulosclerosis (FSGS = 121), membranous nephropathy (MN = 59) and IgA nephropathy (IgAN = 37). 28339906 2018
Entrez Id: 60498
Gene Symbol: IGAN1
IGAN1
0.100 GeneticVariation disease BEFREE Of the 64 patients, 17 were mesangial proliferative glomerulonephritis (MsPGN), 15 were IgA nephropathy (IgAN), 12 were membranous glomerulonephritis (MGN), 11 were focal segmental glomerulosclerosis (FSGS), three were membranous proliferative glomerulonephritis (MPGN), three were immune complex glomerulonephritis (ICGN), two were minimal change disease (MCD), and one was IgM nephropathy (IgMN). 28573371 2017
Entrez Id: 60498
Gene Symbol: IGAN1
IGAN1
0.100 Biomarker disease BEFREE We analyzed 574 IgA nephropathy (IgAN), 175 membranous nephropathy (MGN), and 177 focal segmental glomerulosclerosis (FSGS) cases from 3 Korean kidney centers. 29095250 2017
Entrez Id: 60498
Gene Symbol: IGAN1
IGAN1
0.100 AlteredExpression disease BEFREE The YMs of the renal cortex in patients with membranous nephropathy and IgA nephropathy were significantly higher than those in the patients with CN (p < 0.05). 28332473 2017
Entrez Id: 60498
Gene Symbol: IGAN1
IGAN1
0.100 GeneticVariation disease BEFREE The most common NDKD diagnoses were membranous nephropathy (29.2%), tubulointerstitial nephritis (20.8%) and IgA nephropathy (12.5%). 29130997 2017
Entrez Id: 60498
Gene Symbol: IGAN1
IGAN1
0.100 GeneticVariation disease BEFREE Adjusted transplant rates were highest for patients with IgA nephropathy (IgAN) (referent) and lower for all other groups: focal segmental glomerulosclerosis (HR, 0.80; 95% CI, 0.77-0.82), membranous nephropathy (HR, 0.88; 95% CI, 0.83-0.93), membranoproliferative GN (HR, 0.84; 95% CI, 0.76-0.92), lupus nephritis (HR, 0.69; 95% CI, 0.66-0.71), vasculitis (HR, 0.66; 95% CI, 0.61-0.70), DN (HR, 0.50; 95% CI, 0.47-0.52), ADPKD (HR, 0.85; 95% CI, 0.82-0.88). 28207635 2017
Entrez Id: 60498
Gene Symbol: IGAN1
IGAN1
0.100 Biomarker disease BEFREE The increased mortality risk in the most deprived tertile was not uniform across primary renal diseases, with the association being most marked in focal segmental glomerulosclerosis (HR 7.4) and IgA nephropathy (HR 2.7) and absent in membranous nephropathy. 28639628 2017
Entrez Id: 60498
Gene Symbol: IGAN1
IGAN1
0.100 Biomarker disease BEFREE Case-control studies, used to study specific CKD aetiologies, have yielded risk loci for specific kidney diseases such as IgA nephropathy and membranous nephropathy. 27477491 2016
Entrez Id: 60498
Gene Symbol: IGAN1
IGAN1
0.100 Biomarker disease BEFREE These include anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, IgA nephropathy, anti-phospholipase-A2-receptor (PLA2R) membranous nephropathy and Fabry nephropathy. 25814248 2015
Entrez Id: 60498
Gene Symbol: IGAN1
IGAN1
0.100 Biomarker disease BEFREE Among the different pathological types of PNS, IgA nephropathy (IgAN) and membranous nephropathy (MN) were associated with significantly increased frequencies of the 4G/4G and 4G/5G genotypes, as well as of the 4G allele. 24435552 2014
Entrez Id: 60498
Gene Symbol: IGAN1
IGAN1
0.100 GeneticVariation disease BEFREE The calculated area of RANK mRNA levels under the curve was 0.61 for minimal change disease (MCD), 0.97 for membranous nephropathy (MN), 0.65 for IgA nephropathy (IgAN), 0.70 for lupus nephritis (LN) and 0.70 for focal segmental glomerulosclerosis (FSGS). 25171769 2014
Entrez Id: 60498
Gene Symbol: IGAN1
IGAN1
0.100 Biomarker disease BEFREE The study was conducted in 140 patients with primary chronic GN: mesangial proliferative GN (MesPGN) (n = 49), IgA nephropathy (IgAN) (n = 31), membranous nephropathy (MN) (n = 27), focal segmental glomerulosclerosis (FSGS) (n = 25), membranoproliferative GN (MPGN) (n = 4), and minimal change disease (MCD) (n = 4), and controls (n = 187). 23681285 2014